May 8, 2026
Transferring an API manufacturing process to a contract manufacturing organization (CMO/CDMO) is one of the most critical steps in scaling a drug development program. Yet too often, tech transfers are treated like a simple handoff—when in reality, they require careful preparation, cross-functional collaboration, and technical rigor. A poorly executed tech […]
April 22, 2026
When biotech companies seek funding—whether for a Series A, Series B, IPO, or strategic partnership—investors do not just look at clinical data. They also carefully review CMC information (Chemistry, Manufacturing, and Controls) to evaluate whether the product is manufacturable, scalable, and approvable. CMC readiness can heavily influence investment decisions. Here’s what you need to know […]
April 1, 2026
In drug development, brilliant science alone doesn’t secure regulatory approval—or commercial success. Technical risks related to Chemistry, Manufacturing, and Controls (CMC), regulatory pathways, and manufacturing scalability are often the silent killers of otherwise promising programs. For investors evaluating biotech opportunities, understanding how technical risk evolves from concept to approval is critical to making informed, strategic […]
March 11, 2026
Even with the best process design and operational controls, deviations in API manufacturing are inevitable. The real measure of a company's GMP maturity isn’t whether deviations occur—it’s how they are investigated, documented, and prevented from recurring. Effective deviation management and root cause analysis (RCA) are critical for maintaining regulatory compliance, protecting product quality, and safeguarding clinical and commercial supply. […]
January 28, 2026
For virtual biotechs and lean startups, choosing the right Contract Manufacturing Organization (CMO) is one of the most important decisions in early development. The right partner can be the foundation for smooth IND filings, clinical supply readiness, and future commercialization. The wrong one? It can trigger delays, regulatory issues, budget overruns—and even force you to change vendors […]
January 13, 2026
For CMOs and CDMOs based outside the United States, serving U.S. clients is a major growth opportunity—but it also comes with heightened scrutiny. U.S. sponsors rely heavily on their manufacturing partners to meet FDA CMC and GMP standards, especially when preparing regulatory filings like INDs, NDAs, and BLAs. If your site or processes fall […]
